EU agency backs new cancer drugs from Roche and Algeta/Bayer
LONDON, Sept 20
LONDON, Sept 20 (Reuters) - European regulators have recommended approval of Roche's new breast cancer drug Kadcyla and a prostate cancer medicine, Xofigo, from Algeta and Bayer.
The European Medicines Agency (EMA) said on Friday its experts had also backed Johnson & Johnson's diabetes drug Invokana and Gilead's HIV treatment Viteka.
Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
- Housing, jobs data weaken, but overall economic picture still upbeat
- Putin critic Khodorkovsky free after pardon, heads for Germany |
- Target cyber breach hits 40 million payment cards at holiday peak |
- Pizza outlet attacked as India, U.S. fail to cool diplomat row |
- New York Mayor-elect's reputation for lateness parodied on Twitter